センダキマブの新興薬剤に関する洞察と市場予測：2032年

Cendakimab/RPC4046/CC-93538は、遺伝子組換えヒト化高親和性選択的抗IL-13 mAbです。RPC4046は、IL-13R（α）1およびIL-13R（α）2の両方への結合を阻害するIL-13エピトープに結合することで、有効性および／または安全性において優位性を発揮する可能性があります。本剤は米国FDAよりEoEの治療薬としてODDを取得しています。第Ⅱ相試験においてRPC4046は良好な結果を示し、現在、成人および思春期のEoE患者を対象にCC-93538の有効性と安全性を評価する2つの第Ⅲ相臨床試験を実施中です。

当レポートでは、主要7ヶ国におけるセンダキマブ市場について調査し、市場の概要とともに、2032年までの売上予測、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 好酸球性食道炎（EoE）に対するセンダキマブの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 センダキマブ市場評価

• EoEに対するセンダキマブの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるEoEに対するセンダキマブの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Cendakimab, Clinical Trial Description, 2023
• Table 2: Cendakimab, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Cendakimab Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Cendakimab Market Size in the US, in USD million (2019-2032)
• Table 7: Cendakimab Market Size in Germany, in USD million (2019-2032)
• Table 8: Cendakimab Market Size in France, in USD million (2019-2032)
• Table 9: Cendakimab Market Size in Italy, in USD million (2019-2032)
• Table 10: Cendakimab Market Size in Spain, in USD million (2019-2032)
• Table 11: Cendakimab Market Size in the UK, in USD million (2019-2032)
• Table 12: Cendakimab Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Cendakimab Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Cendakimab Market Size in the United States, USD million (2019-2032)
• Figure 3: Cendakimab Market Size in Germany, USD million (2019-2032)
• Figure 4: Cendakimab Market Size in France, USD million (2019-2032)
• Figure 5: Cendakimab Market Size in Italy, USD million (2019-2032)
• Figure 6: Cendakimab Market Size in Spain, USD million (2019-2032)
• Figure 7: Cendakimab Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Cendakimab Market Size in Japan, USD million (2019-2032)

“"Cendakimab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about cendakimab for eosinophilic esophagitis (EoE) in the seven major markets. A detailed picture of the cendakimab for EoE in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the cendakimab for EoE. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the cendakimab market forecast analysis for EoE in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in EoE.

Drug Summary:

Cendakimab/RPC4046/CC-93538 is a recombinant humanized, high affinity, selective, anti-IL-13 mAb. RPC4046 binds an IL-13 epitope that prevents its binding to both IL-13R (alpha) 1 and IL-13R (alpha) 2, providing potential efficacy and/or safety advantages. The drug has been granted ODD for the treatment of EoE by the US FDA. In the Phase II study, RPC4046 demonstrated positive results, and currently, the company is conducting two Phase III clinical studies to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with EoE.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the cendakimab description, mechanism of action, dosage and administration, research and development activities in eosinophilic esophagitis (EoE).
• Elaborated details on cendakimab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the cendakimab research and development activities in EoE across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around cendakimab.
• The report contains forecasted sales of cendakimab for EoE till 2032.
• Comprehensive coverage of the late-stage emerging therapies for EoE.
• The report also features the SWOT analysis with analyst views for cendakimab in EoE.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Key Questions:

In-depth Cendakimab Market Assessment

This report provides a detailed market assessment of cendakimab for eosinophilic esophagitis (EoE) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

Cendakimab Clinical Assessment

The report provides the clinical trials information of cendakimab for EoE covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for eosinophilic esophagitis (EoE) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence cendakimab dominance.
• Other emerging products for EoE are expected to give tough market competition to cendakimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of cendakimab in EoE.
• Our in-depth analysis of the forecasted sales data of cendakimab from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the cendakimab in EoE.

Key Questions:

• What is the product type, route of administration and mechanism of action of cendakimab?
• What is the clinical trial status of the study related to cendakimab in eosinophilic esophagitis (EoE) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the cendakimab development?
• What are the key designations that have been granted to cendakimab for EoE?
• What is the forecasted market scenario of cendakimab for EoE?
• What are the forecasted sales of cendakimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to cendakimab for EoE?
• Which are the late-stage emerging therapies under development for the treatment of EoE?

Table of Contents

1. Report Introduction

2. Cendakimab Overview in EoE

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Cendakimab Market Assessment

• 5.1. Market Outlook of Cendakimab in EoE
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Cendakimab in the 7MM for EoE
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Cendakimab in the United States for EoE
  • 5.3.2. Market Size of Cendakimab in Germany for EoE
  • 5.3.3. Market Size of Cendakimab in France for EoE
  • 5.3.4. Market Size of Cendakimab in Italy for EoE
  • 5.3.5. Market Size of Cendakimab in Spain for EoE
  • 5.3.6. Market Size of Cendakimab in the United Kingdom for EoE
  • 5.3.7. Market Size of Cendakimab in Japan for EoE

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options